Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
MHLW Seeks New R&D Tax Credit Scheme for Strategic Technologies in FY2026 Proposal
Japan’s Ministry of Health, Labor and Welfare (MHLW) on August 26 released its requests for the FY2026 tax reform, calling for the creation of a new scheme that would grant preferential deduction rates and ceilings for R&D in technologies deemed…
To read the full story
Related Article
- Japan’s FY2026 R&D Tax Credit Reform Wins Broad Industry Backing
April 1, 2026
- Cabinet OKs FY2026 Tax Reform Package, Creates Strategic Tech R&D Credit
January 5, 2026
- Heparinoid, Allergy Drugs among OTC-Like Meds Up for Special Charge Rule
December 24, 2025
- LDP, Ishin Strike Deal on OTC-Like Drugs, Patients to Pay “1/4” Special Charge
December 22, 2025
- LDP, Ishin Finalize FY2026 Tax Reform Outline, Strategic Tech R&D Credit Codified
December 22, 2025
- LDP, Ishin Fail to Seal Deal on OTC-Like Drugs as Talks Stall over Fiscal-Savings Figure
December 18, 2025
- Ishin Urges “Special Charge” Scheme for OTC-Like Drugs, Eyes FY2026 Launch
December 15, 2025
- LDP Tax Panel OKs New 40% R&D Credit for Strategic Technologies
December 12, 2025
- R&D Tax Credit Draws Broad Calls for Maintenance, Expansion: LDP Meeting
December 8, 2025
- Ishin Urges Takaichi to Revisit OTC-Like Drug Coverage, Softens Savings Target
December 5, 2025
- JPMA Chief Presses LDP Study Group to Lock In On-Patent Prices, Scrap “Spillover” Rule
December 5, 2025
- LDP, Ishin to Continue OTC-Like Drug Talks on “Special Charge” Design
December 5, 2025
- LDP Tax Panel Puts R&D Tax Credit on Political-Judgment Track for Further Talks
December 3, 2025
- As Skepticism Emerges, LDP Health Policy Chief Seeks Stronger R&D Tax Credits
November 28, 2025
- LDP Study Group Submits Emergency Proposal to Health Minister, Seeks 5% Drug Price Hike
November 19, 2025
- Pharma, Wholesalers Urge Drug Pricing Overhaul to Address Inflation: LDP Hearing
November 13, 2025
- No Inflation Measures for Drugs Mentioned in FY2026 Budget Request: MHLW Draft
August 25, 2025
- Japan Mulls Preferential R&D Tax Credits for Strategic Technologies in FY2026 Reform Talks
August 22, 2025
- Ruling Parties OK FY2023 Tax Reform Outline; No More Special COVID Measure for R&D Credits
December 19, 2022
REGULATORY
- Trazenta Draws 8 Generic Entrants as Japan Clears New DPP-4 Copies
August 17, 2026
- Stelara IV Biosimilar Can Be Used for Crohn’s Induction: MHLW
August 17, 2026
- PMDA Loses USB Containing Data on 286 People, 27 Companies
August 17, 2026
- MHLW Panel Finalizes Exemptions for OTC-Like Drug Charges
August 17, 2026
- Nakai Tapped as MHLW’s Top Pharmacy Officer; Ohara to Steer Drug Pricing Reform
August 7, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…